Gilead Sciences is a large biotechnology company that researches, develops, and sells medicines. Its recent filings show it lobbies on health issues—especially HIV funding—and on trade matters. The company reported $360,000 in lobbying across four filings, and it hired The Duberstein Group to represent it.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
BENJAMIN R HOWARD
The latest disclosures for this client.
THE DUBERSTEIN GROUP INC.
Q1THE DUBERSTEIN GROUP INC.
Q4YThe entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
THE DUBERSTEIN GROUP INC.
mr DAVID J SCHIAPPA
THE DUBERSTEIN GROUP INC.
KATE WINKLER KEATING
THE DUBERSTEIN GROUP INC.
THE DUBERSTEIN GROUP INC.
Q3THE DUBERSTEIN GROUP INC.
Q2THE DUBERSTEIN GROUP INC.
Q1